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116 Poster Session IIadjusted as needed. Here, we evaluate the pharmacokinetic effects of
concomitant voriconazole administration on blood TAC levels in
27 consecutive allogeneic HSCT recipients (28–64 y; median 55)
in whom pre-emptive dose-modification was used during the first
2 weeks. A total of 170 levels (3–12 per patient; median 5) were
checked between day11 and day116. None of the levels was sub-
therapeutic (\5 ng/mL), and 34 (20%) were .15 ng/mL. 24 of 27
patients required dose-reduction from day 0 to day 11 based on
levels. Each patient required dose-reduction at least twice. An
increase in the dose was needed in only 2 patients after initial
dose-reduction. TAC doses (median, range) on days 0, 7 and 14
were 1.6 (1–2), 0.6 (0.13–1.4), and 0.4 (0.13–1.1) respectively indi-
cating that the median absolute TAC dose, the median TAC mg/
kg dose, and the median per cent TAC dose (100% being the base-
line) declined substantially. However, the median TAC level over
the first 2 weeks remained between 10 and 14.5. It is clear that
lack of pre-emptive dose-reduction would have resulted in TAC
levels climbing steadily. Based on this, we recommend starting
TAC at 0.02–0.022 mg/kg rather than at 0.03 mg/kg if patients
are on concomitant voriconazole, checking levels regularly, and re-
ducing the dose by 30–40% if the 48-h level is 7–10 and by 40–50%
if it is 10–15.314
LOW RELAPSE RATE AFTER ALLOGENEIC-SCT FOLLOWING A MYELOA-
BLATIVE PREPARATIVE REGIMEN WITH FLAMSA CHEMOTHERAPY AND
TOXICITY-REDUCED CONDITIONING IN PATIENTS WITH HIGH RISK
MYELOID MALIGNANCIES AGED 60 YEARS OR OLDER
Schleuning, M.1, Judith, D.1, Heshmat, M.1, Burlakova, I.1, Taube, R.1,
Jedlickova, Z.1, Baurmann, H.1, Kolb, H.-J.2, Schwerdtfeger, R.1. 1Ger-
man Diagnostic Clinic Foundation, Wiesbaden, Germany; 2University of
Munich and GSF Research Center for Environment and Health,Munich,
Germany.
With the introduction of toxicity-reduced conditioning (TRC)
allogeneic stem cell transplantation (allo-SCT) may be considered
also for elderly patients (pts). However, non-myeloablative regi-
mens are associated with a high relapse risk. Our strategy combined
intensive chemotherapy to induce a status of minimal residual dis-
ease, TRC, GVHD prophylaxis with in vivo T-cell depletion and
adjuvant donor lymphocyte transfusions (aDLT). This report sum-
marizes our cumulative experience in a cohort of 45 consecutive el-
derly pts (60–70 y, median 63 y) with myeloid malignancies (18 with
high risk cytogenetics) treated with the FLAMSA-RIC protocol,
consisting of a 4-day course of chemotherapy (AraC 2 g/m2, Fludar-
abine 30 mg/m2 and Amsacrine 100 mg/2) followed by 3 days rest
and TRC with 4Gy TBI, cyclophosphamide and antithymocyte
globuline prior to allo-SCT. The underlying diseases were AML
(de novo n 5 20; sAML n 5 16) or progressive MDS (n 5 8) with
only 5 pts being in CR at the time of transplant. One pt suffered
from CML in refractory myeloid blast crisis. To further reduce tox-
icity TBI was replaced by intravenous Busulfan (8  3.2 mg/kg) in
the last 16 pts. All but one pt received mobilized peripheral blood
stem cells as graft and 9 pts had a sibling and 36 an unrelated donor.
GVHD prophylaxis consisted of Cyclosporine A and MMF. The
procedure as a whole was clearly myeloablative as evidenced by
full donor chimerism at d1 30 in all pts. Engraftment occurred af-
ter 10–48 d (median 18 d). Of 25 eligible pts (being alive and free of
leukaemia at d 1 120) 8 pts actually received aDLT and none of
these relapsed. Despite the high relapse risk we observed only 6
deaths because of recurrent leukaemia. Severe acute GVHD oc-
curred in 20% and the non relapse mortality was 31% with 3 pts dy-
ing from GVHD, 10 from infection and one from cardiac failure.
With a median follow-up of 10 months for surviving pts the Ka-
plan-Meyer procedure estimates a 43% probability of survival at 2
y after transplantation. Although, the follow-up of pts having re-
ceived i.v. Busulfan is rather short there seems to be a strong ten-
dency of further reduced toxicity without increased relapse
incidence in this cohort. Our data support the notion that toxic-
ity-reduced but still myeloablative conditioning followed by allo-
SCT from related or unrelated donors can safely be applied in el-
derly pts with high risk myeloid malignancies and provides an excel-
lent platform for adoptive immunotherapy after induction of
tolerance.315
SIMILAR SURVIVAL AFTER SIBLING VS UNRELATED DONOR ALLOGE-
NEIC STEM CELL TRANSPLANTATION WITH REDUCED INTENSITY CON-
DITIONING
Stein, S., Goldstein, S.C., Smith, J., Luger, S., Loren, A.,
Stadtmauer, E., Schuster, S., Nasta, S., Tsai, D., Perl, A.,
Andreadis, B., Frey, N., Kasner, M., Cole, S., Hinkle, J., Porter, D.L.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Although recent studies have shown comparable survival out-
comes between unrelated donor (URD) and sibling donor stem
cell transplantation in the myeloablative transplant setting, little
comparative data based on donor source is available in the setting
of non-myeloablative/reduced intensity conditioning (RIC), where
it is presumed that GvL effects must play a key role in long term sur-
vival. In this retrospective analysis, we compare the outcome of 111
patients receiving RIC followed by either matched sibling (n 5 65)
or unrelated donor (n 5 46) peripheral blood stem cell (PBSC)
transplantation for hematologic malignancies. All patients were
deemed ineligible for myeloablative conditioning based on institu-
tional standards for age, comorbid disease, and/or prior therapy. All
sibling and 38 of 46 unrelated recipients received A, B, DR matched
grafts. The median recipient age in both cohorts was identical; sib-
ling 52 y (range 12–75 y) and unrelated 52 y (range 29–69 y). Con-
ditioning regimens were primarily fludarabine/cytoxan-based in
both cohorts, with URD recipients skewed toward the addition of
Alemtuzumab pre-transplant (69% URD vs 25% sib), and the use
of TBI 200 for 21/23 myeloma pts. The distribution of diagnoses
was similar between both cohorts in patients with lymphoid malig-
nancies (NHL, HD, CLL n5 66) 34 sib vs 32 URD, and leukemia/
MDS (n5 22), 10 sib vs 12 URD; the diagnosis of myeloma (n5 23)
was skewed toward sibling donors (21 vs 2 URD). Kaplan-Meier es-
timate of overall survival (OS) for all patients at 2 years was 31%. At
a median f/u of 43 weeks in both cohorts, overall survival was nearly
identical (57% sibs; 55% URD). Of note, there was no statistically
significant difference in 2 year OS between sibling and URD recip-
ients (p5 0.25), nor was there a difference in K-M estimates of OS
between sibling and URD recipients when patients with lymphoid
and myeloid disease were analyzed separately. Among expired pa-
tients, there was no difference in the incidence of disease-related
(26/42 sibs vs 18/32 URD) or treatment-related [organ failure,
infection and GvHD] (16/42 sibs vs 14/32 URD) causes of death.
Furthermore, a statistically significant higher proportion of
GvHD-related death among URD patients was not seen. These
data support the pursuit of unrelated donors for RIC transplanta-
tion as an alternative to sibling donors without compromising over-
all survival.316
DEVELOPMENT AND ANTI-BALB.B REACTIVITY OF T CELLS EMERGING
FROM BONE MARROW CELLS TRANSDUCEDWITH A CLONAL TCRVb14-
Jb2.4 SEQUENCE
Appel, M.Y.1, Friedman, T.M.2, Korngold, R.2. 1Thomas Jefferson Uni-
versity, Philadelphia, PA; 2Hackensack University Medical Center,
Hackensack, NJ.
In previous experiments utilizing spectratype-sequencing, we re-
ported a dominant T cell receptor (TCR) Vb14-Jb2.4 sequence
prevalent in the thoracic duct lymphocyte (TDL) population of ir-
radiated BALB. B mice transplanted with C57BL/6 (B6) mouse
bone marrow and CD81 T cells. CD4-dependent CD81 Vb141
T cells mediate lethal graft versus host disease (GVHD) in
a B6/BALB. B transplantation model. Therefore, we wanted to
investigate the alloreactive potential of T cells expressing the partic-
ular isolated TCRb sequence. We harvested bone marrow from 5-
fluorouracil (5-FU) treated TCRb-/- mice. The bone marrow cells
were retrovirally transduced with a construct containing the cDNAs
for Green Fluorescent Protein (GFP) and the specific Vb14-Jb2.4
TCR sequence. The marrow was then used to reconstitute irradi-
ated B6 mice. 20–40% of the peripheral blood mononuclear cells
(PBMC) in these mice were GFP1Vb141, of which greater than
95% were CD41 and 1–4% were CD81. When the marrow was
used to reconstitute MHC II-/- mice, bred to a B6 background,
